Current concepts in the management of hemophilia.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000700:Analgesics / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D003613:Danazol / Q000627:therapeutic use; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D005164:Factor IX / Q000627:therapeutic use; D005169:Factor VIII / Q000627:therapeutic use; D005340:Fibrinogen / Q000627:therapeutic use; D006395:Hemarthrosis / Q000628:therapy; D006467:Hemophilia A / Q000150:complications / Q000628:therapy*; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010949:Plasma; D014842:von Willebrand Diseases / Q000175:diagnosis / Q000628:therapy
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D000933:Antifibrinolytic Agents; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005164:Factor IX; D005340:Fibrinogen; D003894:Deamino Arginine Vasopressin; D003613:Danazol